Therapeutics News and Research

RSS

Intralytix awarded U.S. patent for bacteriophage treatment of colonization by pathogenic bacteria

Intralytix, Inc., announced today that it has been issued a patent by the U.S. Patent & Trademark Office covering the use of bacteriophages to reduce the risk of bacterial infection in persons colonized with pathogenic bacteria including MRSA.

10 Dec 2008

Alnylam Pharmaceuticals update on Kreutzer-Limmer patent estate

Alnylam Pharmaceuticals, Inc. has announced that the European Patent Office (EPO) has ruled in favor of the Appellants in oral proceedings before the Board of Appeals related to the '623 (EP 1144623) patent in its Kreutzer-Limmer patent estate.

10 Dec 2008

Cytori reports benefit of adipose-derived regenerative cells in spinal disc model

Cytori Therapeutics, Inc. reported preclinical study results, which demonstrate the potential benefit of adipose-derived stem and regenerative cells (ADRCs) for the treatment of damaged intervertebral discs, evidenced by significantly increased disc tissue density and disc-specific extracellular matrix components at 12-months post treatment in a large animal model.

8 Dec 2008

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical trials, according to researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

8 Dec 2008

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

Allos Therapeutics, Inc. has announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate (PDX) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), at the 50th Annual Meeting of the American Society of Hematology (abstract 261).

8 Dec 2008

Motor neurons derived from human embryonic stem cells provide insight into ALS

Two new research studies use motor neurons derived from human embryonic stem (hES) cells to demonstrate that multiple toxic pathways contribute to the devastating degeneration associated with Amyotrophic Lateral Sclerosis (ALS) and that protective therapeutics will need to oppose the disease on multiple fronts.

3 Dec 2008

Intradigm issued new RNAi therapeutics patent

Intradigm Corporation has announced the issuance of United States patent 7,459,547, entitled "Methods and Compositions for Controlling Efficacy of RNA Silencing."

3 Dec 2008

Horizon Therapeutics announces HZT-501 trials meet primary endpoints

Horizon Therapeutics, Inc. has announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints.

3 Dec 2008

FDA accepts Zevalin supplemental biologics license application

Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.

1 Dec 2008

New cell analysis platform developed - commercial partners sought

Sandia National Laboratories is seeking commercial partners to license or contribute to the continued development of a new lab-on-a-chip platform for high-throughput manipulation and interrogation of individual cells, one that enables quantitative analysis of cellular behaviors with unprecedented speed, resolution, sensitivity, and multiplexing.

1 Dec 2008

Crossing scientific boundaries to understand the rejection of drugs

A physicist from The University of Nottingham and a mathematical modeller from The University of Southampton are joining forces in the hope of answering a biological mystery - how do our bodies reject some of the drugs that are sent to cure us?

30 Nov 2008

Multitasking proteins driving cell behavior

A study describing how cells within blood vessel walls move en masse overturns an assumption common in the age of genomics - that the proteins driving cell behavior are doing so much multitasking that it would be near impossible to group them according to a few discrete functions.

30 Nov 2008

Novel target for therapeutics against Staphylococcus aureus

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to cause methicillin-resistant Staphylococcus aureus (MRSA) infections, a finding that could aid in developing therapeutics against the potentially deadly disease.

28 Nov 2008

EpiVax receives grant for $390,000 to optimize HIV vaccine delivery

EpiVax, Inc., a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine.

26 Nov 2008

Scientists reconstruct bat variant of SARS coronavirus

Researchers at the University of North Carolina at Chapel Hill and Vanderbilt University Medical Center have synthetically reconstructed the bat variant of the SARS coronavirus (CoV) that caused the SARS epidemic of 2003.

25 Nov 2008

Non-pharmacologic interventions for the control of osteoporosis and obesity

The Department of Biomedical Engineering at Stony Brook University received a $1.8 million grant from the National Institutes of Health (NIH) to investigate the biologic and physical mechanisms of very low-magnitude mechanical signals and how they strengthen bone and muscle.

20 Nov 2008

Possible new target for anticancer therapeutics

New data, generated in mice, by Pierre Sonveaux and colleagues, at University catholique de Louvain, Belgium, have identified a potential new target for anticancer therapeutics.

20 Nov 2008

Lactic acid found to be important energy source for tumor cells

Many tumors have cells that burn fuel for activities in different ways. Tumor cells near blood vessels have adequate oxygen sources and can either burn glucose like normal cells, or lactic acid (lactate). Tumor cells further from vessels are hypoxic and inefficiently burn a lot of glucose to keep going. In turn, they produce lactate as a waste product.

20 Nov 2008

Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy

One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors.

20 Nov 2008

Cytori announces seven new investigator-initiated clinical studies in Japan

All seven studies are investigator-initiated and to be performed under local and country guidelines. Cytori, who will not sponsor these studies, will continue work with country authorities, such as the Ministry of Health and Labor in Japan, to obtain specific regulatory approvals for its products.

19 Nov 2008